STAT Plus: Bruised by Wall Road, Ovid Therapeutics could also be one step nearer to vindication with uncommon illness drug

Ovid Therapeutics (OVID) could also be one step nearer to vindication with a uncommon illness therapy whose polarizing outcomes led Wall Road to all however abandon the small drug firm.

After a gathering with the Meals and Drug Administration, Ovid is taking its remedy for the debilitating Angelman syndrome right into a late-stage trial, one that can use the identical definition of success employed in a previous research. The corporate mentioned Thursday that the FDA agreed with its strategy to figuring out whether or not Angelman sufferers are getting higher. And which means Ovid may win FDA approval by replicating what it noticed in an earlier trial.

Unlock this text by subscribing to STAT Plus and luxuriate in your first 30 days free!


What’s it?

STAT Plus is a premium subscription that delivers every day market-moving biopharma protection and in-depth science reporting from a crew with many years of trade expertise.

What’s included?

Authoritative biopharma protection and evaluation, interviews with trade pioneers, coverage evaluation, and first appears at leading edge laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only stay chats with our reporters and consultants within the subject
Discounted tickets to trade occasions and early-bird entry to trade stories